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Conclusions: Pretreatment levels of MGMT and MLH1/MSH2 protein levels are not predictive of response to TMZ in MF/SS, suggesting that other resistance mechanisms are important.
Introduction
The pathogenesis of mycosis fungoides/Sézary syndrome (MF/SS) is characterized by an altered immune biology and the accumulation of cytogenetic abnormalities during disease progression 1 . Evidence of epigenetic silencing of hypermethylation of individual genes or gene-specific promoters associated with tumor progression has been observed in advanced stages of cutaneous T-cell lymphoma (CTCL) 2 3 . Microsatellite instability (MSI), consistent with deficits in DNA repair, was found in a large number of microdissected tissue samples from patients with MF with a higher prevalence in tumor stages suggesting a multilineage progression.
Chromosomal and somatic mutations have been frequently demonstrated in hereditary nonpolyposis colon carcinoma and correlated with mismatch repair gene defects and microsatellite instability [4] [5] [6] . In addition, several reports have identified the loss of mismatch repair function leading to microsatellite instability in a number of leukemias and lymphomas 7 .
Temozolomide (TMZ) is an oral imidazotetrazine-derivative of dacarbazine that has demonstrated clinical activity in various tumor types such as non-Hodgkin lymphoma, brain tumors, and melanoma [8] [9] [10] . It is generally well tolerated with an excellent oral bioavailability. TMZ causes methylation damage on DNA including the O Author Manuscript Published OnlineFirst on July 11, 2011; DOI: 10.1158/1078-0432.CCR- Resistance has been associated with high levels of the DNA repair protein O 6 -methylguanine-DNA methyltransferase (MGMT), also referred to as O 6 -alkylguanine-DNA alkyltransferase (AGT), and defects of DNA mismatch repair 11 . Prior studies have shown that increased levels of MGMT in tumor samples of patients with brain tumors receiving carmustine (bischloroethylnitrosourea, BCNU) or temozolomide therapy are associated with resistance to chloroethylating and methylating agents 12 13 . Moreover, MGMT levels in tumor tissue specimen may be a predictive marker of survival in this patient population 14 . The loss of mismatch repair function is associated with tumor progression during TMZ treatment 15 . Interestingly, MGMT expression varies considerably in normal skin tissue shown by previous cell-type specific specifu in situ mapping for MGMT.
Topical BCNU is an effective treatment for patch-and plaque-stage MF 17 18 . Based on these unique findings, MGMT protein levels were studied by quantitative immunofluorescence in MF patch, plaque, and tumor tissue samples as well as in blood and lymph node samples. Overall, low levels of MGMT protein were detected, but virtually undetectable in malignant CD4 + T-cells in samples from patch/plaque disease with higher levels in tumor lesions, circulating Sézary cells, and lymph nodes 19 . Healthy donor CD4-T-cells and skin samples of benign reactive dermatitides had also low or nondetectable levels of MGMT expression.
No treatment is considered to be curative and patients with advanced MF/SS are often refractory to therapy and have a poor prognosis with a 5-year survival rate of less than 40% 20 21 . Low levels of MGMT in malignant CD4 
Methods

Patient Selection
The current study (trial registration ID: NCT00004106) was approved by the local Twenty-five percent dose reductions were required in patients with any grade 3 toxicity and 50% dose reduction with any grade 4 toxicity that delayed treatment. Re-escalation was not allowed. All grade 2 to 4 toxicities must have resolved to at least grade 1 prior to repeat dosing. If grade 3 hematologic toxicities persisted for more than 3 weeks, the patient was discontinued from the study. Growths factors were not allowed. Therapy was permanently discontinued if grade 3 to 4 toxicity reoccurred.
Patient Monitoring and Response Classification
The disease status of all patients was monitored at least once every 2 weeks during the first 2 cycles and thereafter on day 1 of each subsequent cycle with appropriate physical examination, complete blood cell count, Sézary cell count, and biochemical profile to assess the effect of TMZ. Imaging studies at 2 months were performed to follow lymphadenopathy and systemic disease if present. The Severity-Weighted Assessment Tool (SWAT) was used to quantify skin disease burden. Criteria for response were Author Manuscript Published OnlineFirst on July 11, 2011; DOI: 10.1158/1078-0432.CCR-11-0556 defined as followed: complete response (CR), complete resolution of cutaneous and/or extracutaneous disease, and Sézary cell count for at least 4 weeks; partial response (PR), at least 50% reduction of index lesions or Sézary cell count with no evidence of new lesions, for at least 4 weeks; stable disease (SD), less than 50% reduction of index lesions or Sézary cell count; progressive disease (PD), a greater than 25% increase in cutaneous or extracutaneous disease, or Sézary cell count. A Sézary cell count of less than 5% was considered not significant.
Analysis for MGMT, and MLH1 and MSH2 Mismatch Repair Proteins
Skin biopsies and blood samples were taken from patients prior to study entry. Isolation of malignant CD4+ T-cells from peripheral blood samples and subsequent determination of MGMT protein levels by quantitative immunofluorescence were performed as previously published 19 22 . Paraffin-embedded skin biopsies from 24 patients were analyzed for MGMT and for mismatch repair proteins mutL homolog 1 (MLH1) and mutS homolog 2 (MSH2) by quantitative immunofluorescence according to previously described methods 19 and/or by semiquantitative immunohistochemistry. For all 3 markers only nuclear staining was taken into account for the respective scoring system. A semiquantitative scoring on a four-point scale based on the percentage of positively staining tumor cells was employed according to the indicated references (<10%: 0, 10-30%: 1, 30-50%: 2, >50%: 3). For statistical analysis, groups of negative and weak staining (score 0 and 1) or moderate and strong staining (scores 2 and 3) were combined. 
Statistical Methods
All statistical analysis was based on 29 enrolled patients. Baseline variables for each treatment group were summarized as determined statistically by Fisher's Exact Test.
Overall survival and disease-free-survival was analyzed using the Kaplan-Meier method.
The chi-square test was used to test differences in response rates between disease with a high or low expression of MGMT, MLH1, and MSH2. P < 0.05 was considered significant.
Results
Patient Characteristics
The majority of patients were Caucasian and presented with a median age of 61 years 
Twenty-six patients were evaluable for response excluding 3 patients who discontinued therapy within the first cycle, due to toxicity (2 patients) or unknown reasons (1 patient). low or negative in patients who responded to or remained stable on TMZ therapy and further supports the concept that low MGMT expressing cells are preferentially killed by TMZ, but these findings did not reach statistical significance. This is likely due to a small number of patients studied. In addition, all patients had advanced disease and were heavily pretreated, leading to further accumulation of mutations that may influence other critical pathways in controlling cellular response to TMZ.
MSI has been recently shown to be associated with disease progression in MF 3 23 . Such progressive genetic defects have been extensively demonstrated in hereditary colon carcinoma and correlated with DNA mismatch repair defects 4 . Defects in mismatch repair may result in cellular resistance to TMZ, independent of MGMT activity. In a recent analysis, a panel of mismatch repair proteins appeared normal in skin biopsies of patients with MF/SS 24 . Our results suggest that a detectable positive MLH1 and/or MSH2 score was higher in patients who responded to TMZ, but this was not found to be significantly correlated with response rate or overall disease control. It appears that TMZ resistance is not related to a dysfunctional MLH1/MSH2; however, we were not able to study the mismatch repair protein expression during or after completion of treatment and therefore do not know whether their expression has been altered by TMZ. It may also be plausible that dysfunctional MLH1/MSH2 does not play a causal role in tumor progression in our patient population, but studies that rely on mutation frequency and functional data have not been done. In addition, the methodologies applied in the current study may not be sensitive enough to detect subtle differences in MGMT and mismatch repair to better define resistance to TMZ therapy. Eight patients were found to be 
previously treated with topical or systemic alkylating agents either alone or in combination. We therefore cannot exclude any effects of these agents on the current regimen as well.
The toxicity profile using the standard five-day dosing regimen of TMZ (200 mg/m 2 ) was safe and feasible with the majority of toxicities being Grade 1 or 2 in severity and transient. Most patients received more than two cycles of TMZ. The major reason for the discontinuation of treatment was tumor progression. The treatment was discontinued in 3 patients following Grade 3 thrombocytopenia, lymphopenia, and skin reaction.
In conclusion, the current trial confirms that TMZ has moderate activity in patients with advanced CTCL. Furthermore, our analysis of the pretreatment levels of MGMT and MLH1/MSH2 in skin biopsies failed to predict response to TMZ. However, most of our patients had advanced disease which might have contributed genetic alterations involving other repair pathways. One strategy to reverse the limited therapeutic efficacy to TMZ is inactivation of MGMT with protracted dosing regimen, but this may be of limited efficacy due to increased hematological toxicity as previously reported 25 . Clinical trials depleting MGMT activity with O 6 -benzylguanine have been shown to potentiate the cytotoxic activity of BCNU in patients with multiple myeloma and advanced melanoma, but at the expense of significantly increased hematologic toxicity 26 27 . In contrast, 
